1
|
Rossi M, Mele C, Rossetto Giaccherino R, Meomartino L, Brero D, Marsan G, Aimaretti G, Ghigo E, Pagano L. Post-Surgical Indications to Radioiodine Treatment and Potential Risk Factors for Post-Treatment Recurrence in Patients with Intermediate-Risk Differentiated Thyroid Carcinoma. J Pers Med 2023; 13:jpm13050775. [PMID: 37240945 DOI: 10.3390/jpm13050775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Revised: 04/20/2023] [Accepted: 04/28/2023] [Indexed: 05/28/2023] Open
Abstract
In this multicentric retrospective observational study, we investigated the potential risk factors for radioiodine (RAI) indication and the post-treatment recurrence of intermediate-risk differentiated thyroid cancer (DTC) 1 and 3 years from diagnosis. We included 121 patients who underwent thyroidectomy for intermediate-risk DTC. The 92 patients (76.0%) who underwent RAI treatment had a higher prevalence of extra-thyroid micro-extension (mETE) (p = 0.03), pT3 staging (p = 0.03) and recourse to therapeutic central (p = 0.04) and lateral (p = 0.01) neck dissection, as well as higher numbers (p = 0.02) and greater dimensions (p = 0.01) of lymph node metastases, compared with untreated patients. Relapse was observed in 18.1% and 20.7% of cases 1 and 3 years from diagnosis, respectively, with no significant differences between groups. A lower age at diagnosis (p = 0.03) and higher levels of stimulated thyroglobulin (Tg) (p = 0.04) emerged as the only independent risk factors for tumour relapse at 1 year. Tumour relapse at 3 years was only independently predicted by the presence of tumour relapse at 1 year (p = 0.04). In conclusion, mETE, pT3 and the presence of large, multiple or clinically evident lymph node metastases represent the main indicators for referring patients to RAI treatment. Early recurrence may be considered the most relevant factor when planning further surveillance.
Collapse
Affiliation(s)
- Mattia Rossi
- Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
| | - Chiara Mele
- Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, 28100 Novara, Italy
| | - Ruth Rossetto Giaccherino
- Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
| | - Letizia Meomartino
- Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
| | - Denise Brero
- Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
| | - Giulia Marsan
- Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, 28100 Novara, Italy
| | - Gianluca Aimaretti
- Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale, 28100 Novara, Italy
| | - Ezio Ghigo
- Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
| | - Loredana Pagano
- Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
| |
Collapse
|
2
|
Thyroglobulin expression, Ki-67 index, and lymph node ratio in the prognostic assessment of papillary thyroid cancer. Sci Rep 2023; 13:1070. [PMID: 36658256 PMCID: PMC9852547 DOI: 10.1038/s41598-023-27684-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Accepted: 01/05/2023] [Indexed: 01/21/2023] Open
Abstract
The clinical significance of thyroglobulin (Tg) expression in papillary thyroid cancer (PTC) has not been systematically explored in relation to the Ki-67 index, lymph node ratio (LNR), or other conventional prognostic predictors. In this retrospective study of 327 patients with PTC, we investigated the immunohistochemical expression of Tg in both primary tumors and their matching lymph node metastases in relation to the Ki-67 index, LNR, and clinical data. Tumoral Tg immunoreactivity was inversely correlated to the Ki-67 index and tumor recurrence. The Ki-67 index was higher in lymph node metastases (mean 4%) than in the primary tumors (mean 3%). Reduced Tg expression, estimated as 0-25% Tg positive tumor cells, was more common in lymph node metastases compared to primary tumors. In addition to advanced metastatic burden (defined as N1b stage and LNR ≥ 21%), low Tg expression (0-25% positive tumor cells) in lymph node metastases had a significant prognostic impact with shorter recurrence-free survival. These findings support the potential value of histopathological assessment of Tg expression and Ki-67 index in lymph node metastases as complementary predictors to anticipate the prognosis of PTC patients better.
Collapse
|
3
|
A Stepwise Approach Using Metastatic Lymph Node Ratio-Combined Thyroglobulin for Customization of [ 18F]FDG-PET/CT Indication to Detect Persistent Disease in Patients with Papillary Thyroid Cancer. Diagnostics (Basel) 2021; 11:diagnostics11050836. [PMID: 34066574 PMCID: PMC8148441 DOI: 10.3390/diagnostics11050836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2021] [Revised: 05/02/2021] [Accepted: 05/04/2021] [Indexed: 11/17/2022] Open
Abstract
We investigated whether an indication for [18F]FDG-PET/CT to detect FDG-avid persistent disease (PD) could be identified precisely using the extent of metastatic lymph nodes (MLNs) and serum thyroglobulin (Tg) in papillary thyroid cancer (PTC) patients. This retrospective study included 429 PTC patients who underwent surgery and radioactive iodine (RAI) therapy. [18F]FDG-PET/CT and serum Tg were evaluated just before RAI therapy. The MLN ratio (LNR) was defined as the ratio of the number of MLNs to the number of removed LNs. To derive the LNR-combined criteria, different Tg cut-off values for identifying the PET/CT-indicated group for PD detection were applied individually to subgroups initially classified based on LNR cut-off values. The cut-off values for serum Tg, the number of MLNs, and LNR for a PET/CT indication were 6.0 ng/mL, 5, and 0.51, respectively. Compared to a single parameter (serum Tg, total number of MLNs, and LNR), the LNR-combined criteria showed significantly superior diagnostic performance in detecting FDG-avid PD (p < 0.001). The diagnostic performance of PET/CT in detecting FDG-avid PD was significantly improved when the PET/CT-indicated group was identified through the LNR-combined criteria in a stepwise manner; this can contribute to a customized PET/CT indication in PTC patients.
Collapse
|
4
|
Kim HK, Yoon JH, Cho JS, Kwon SY, Yoo SW, Kang HC. The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer. Korean J Intern Med 2020; 35:1164-1172. [PMID: 31352718 PMCID: PMC7487314 DOI: 10.3904/kjim.2018.173] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Accepted: 08/29/2018] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND/AIMS This study was conducted to identify prognostic factors in patients with papillary thyroid cancer (PTC) at the time of first radioactive iodine (RAI) therapy, and to evaluate the clinical value of the thyroglobulin (Tg) increase after RAI. METHODS Serum Tg was sampled prior to (pre-Tg) and 7 days after RAI (post-Tg) in 680 patients with PTC. Patients were classified into excellent response (ER), biochemical incomplete response (BCIR), structural incomplete response (SIR), and indeterminate response (IR) groups using dynamic risk stratification at 6 to 18 months after RAI therapy. RESULTS After RAI therapy, 514 patients (75.6%) had an ER, 34 (5.0%) had a BCIR, 13 (2.0%) had an SIR, and 119 (17.5%) had an IR. Pre-Tg level was significantly different among the groups, with the highest level being in the SIR group, followed by the BCIR, IR, and ER groups. However, post-Tg levels were not different among the groups. Post-Tg level increased significantly after RAI therapy compared to the pre-Tg level (mean 13.8 ± 32.2 ng/mL vs. 2.5 ± 8.9 ng/mL). In 422 patients whose pre-Tg level was < 1 ng/mL, 205 had post-Tg levels < 1 ng/mL, while 167 had post-Tg levels of 1 to 10 ng/mL, and 50 had levels > 10 ng/mL. No difference was observed in the response to therapy. Differences in RAI dose and uptake pattern were observed among the three groups. CONCLUSION Pre-Tg was useful as a prognostic factor in patients with PTC. In patients with low pre-Tg, increased post-Tg may reflect remnant tissue and does not help predict the prognosis.
Collapse
Affiliation(s)
- Hee Kyung Kim
- Departments of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
| | - Jee Hee Yoon
- Departments of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
| | - Jin Seong Cho
- Departments of Surgery, Chonnam National University Medical School, Gwangju, Korea
| | - Seong Young Kwon
- Departments of Nuclear Medicine, Chonnam National University Medical School, Gwangju, Korea
| | - Su Woong Yoo
- Departments of Nuclear Medicine, Chonnam National University Medical School, Gwangju, Korea
| | - Ho-Cheol Kang
- Departments of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
- Correspondence to Ho-Cheol Kang, M.D. Department of Internal Medicine, Chonnam National University Medical School, 160 Baekseo-ro, Dong-gu, Gwangju 61469, Korea Tel: +82-61-379-7620 Fax: +82-61-379-7628 E-mail:
| |
Collapse
|
5
|
Liu H, Yang D, Li L, Tu Y, Chen C, Sun S. Appraisal of radioiodine refractory thyroid cancer: advances and challenges. Am J Cancer Res 2020; 10:1923-1936. [PMID: 32774993 PMCID: PMC7407348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Accepted: 06/16/2020] [Indexed: 06/11/2023] Open
Abstract
The incidence of thyroid cancer ranks top among all endocrine cancers, which has increased worldwide. Some patients suffer from recurrent/residual diseases after primary treatment. The recurrent/residual disease often turns out to be radioiodine refractory and shows poor response to radioiodine therapy. A lot of studies have explored the precise appraisal of radioiodine refractory disease in recent years. The mechanism of iodine uptake and the definition of radioiodine refractory disease have been summarized and discussed. The advances in tumor characteristics, histologies, and mutant conditions have been explored for a more accurate method in the early-stage appraisal. We then offer a review of opinions in the evaluation of refractory disease during follow-up, including Tg doubling time, 18F PET/CT, 131I WBS, and others. The sensitivity and specificity have been compared between different diagnostic methods. Some novel methods may be introduced for more precise appraisal, such as a scoring system and RNA expression profiling. This review aims to provide physicians a broad insight into the appraisal of radioiodine refractory disease and to pave way for future study.
Collapse
Affiliation(s)
- Hanqing Liu
- Department of Thyroid and Breast Surgery, Renmin Hospital of Wuhan UniversityWuhan 430060, PR China
| | - Dan Yang
- Department of Cardiology, Renmin Hospital of Wuhan UniversityWuhan 430060, PR China
- Hubei Key Laboratory of Metabolic and Chronic DiseasesWuhan 430060, PR China
| | - Lingrui Li
- Department of Thyroid and Breast Surgery, Renmin Hospital of Wuhan UniversityWuhan 430060, PR China
| | - Yi Tu
- Department of Thyroid and Breast Surgery, Renmin Hospital of Wuhan UniversityWuhan 430060, PR China
| | - Chuang Chen
- Department of Thyroid and Breast Surgery, Renmin Hospital of Wuhan UniversityWuhan 430060, PR China
| | - Shengrong Sun
- Department of Thyroid and Breast Surgery, Renmin Hospital of Wuhan UniversityWuhan 430060, PR China
| |
Collapse
|
6
|
Optimization of Predictive Performance for the Therapeutic Response Using Iodine Scan-Corrected Serum Thyroglobulin in Patients with Differentiated Thyroid Carcinoma. Cancers (Basel) 2020; 12:cancers12020262. [PMID: 31978980 PMCID: PMC7072233 DOI: 10.3390/cancers12020262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2019] [Revised: 01/17/2020] [Accepted: 01/21/2020] [Indexed: 11/16/2022] Open
Abstract
We investigated whether the performance of serum thyroglobulin (Tg) for response prediction could be improved based on the iodine uptake pattern on the post-therapeutic I-131 whole body scan (RxWBS) and the degree of thyroid tissue damage with radioactive iodine (RAI) therapy. A total of 319 patients with differentiated thyroid carcinoma who underwent total thyroidectomy and RAI therapy were included. Based on the presence/absence of focal uptake at the anterior midline of the neck above the thyroidectomy bed on RxWBS, patients were classified into positive and negative uptake groups. Serum Tg was measured immediately before (D0Tg) and 7 days after RAI therapy (D7Tg). Patients were further categorized into favorable and unfavorable Tg groups based on the prediction of excellent response (ER) using scan-corrected Tg developed through the stepwise combination of D0Tg with ratio Tg (D7Tg/D0Tg). We investigated whether the predictive performance for ER improved with the application of scan-corrected Tg compared to the single Tg cutoff. The combined approach using scan-corrected Tg showed better predictive performance for ER than the single cutoff of D0Tg alone (p < 0.001). Therefore, scan-corrected Tg can be a promising biomarker to predict the therapeutic responses after RAI therapy.
Collapse
|
7
|
Song M, Jeon S, Kang SR, Jabin Z, Yoo SW, Min JJ, Bom HS, Cho SG, Kim J, Song HC, Kwon SY. Response Prediction of Altered Thyroglobulin Levels After Radioactive Iodine Therapy Aided by Recombinant Human Thyrotropin in Patients with Differentiated Thyroid Cancer. Nucl Med Mol Imaging 2018; 52:287-292. [PMID: 30100941 DOI: 10.1007/s13139-018-0528-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2018] [Revised: 04/16/2018] [Accepted: 05/23/2018] [Indexed: 11/26/2022] Open
Abstract
Purpose Thyroglobulin (Tg) may be released from damaged residual thyroid tissues after radioactive iodine (RAI) therapy in patients with differentiated thyroid carcinoma (DTC). We investigated whether altered levels of serum Tg after recombinant human thyrotropin (rhTSH)-aided RAI therapy could be a prognostic marker in patients with DTC. Methods We evaluated 68 patients who underwent RAI therapy after total thyroidectomy. Serum Tg levels were measured just before RAI administration (D0Tg) and 7 days after RAI therapy (D7Tg). Patients with a D0Tg level greater than 2.0 ng/mL were excluded to more precisely evaluate the injury effect of RAI in small remnant tissues. The ratioTg was defined as the D7Tg level divided by that on D0Tg. The therapeutic responses were classified as acceptable or non-acceptable. Finally, we investigated which clinicopathologic parameters were associated with therapeutic response. Results At the follow-up examination, an acceptable response was observed in 50 patients (73.5%). Univariate analysis revealed significant differences in N stage (P = 0.003) and ratioTg (acceptable vs. non-acceptable responses, 21.9 ± 33.6 vs. 3.8 ± 6.5; P = 0.006). In multivariate analysis, only ratioTg significantly predicted an acceptable response (odds ratio 1.104; 95% confidence interval 1.005-1.213; P = 0.040). A ratioTg above 3.5 predicted an acceptable response with a sensitivity of 66.0%, specificity of 83.3%, and accuracy of 70.6% (area under the curve = 0.718; P = 0.006). Conclusions Altered levels of serum Tg after RAI therapy, calculated as the ratioTg (D7Tg/D0Tg), significantly predicted an acceptable response in patients with DTC.
Collapse
Affiliation(s)
- Minchul Song
- 1Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 58128 South Korea
| | - Subin Jeon
- 1Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 58128 South Korea
| | - Sae-Ryung Kang
- 1Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 58128 South Korea
| | - Zeenat Jabin
- 1Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 58128 South Korea
| | - Su Woong Yoo
- 1Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 58128 South Korea
| | - Jung-Joon Min
- 1Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 58128 South Korea
| | - Hee-Seung Bom
- 1Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 58128 South Korea
| | - Sang-Geon Cho
- 2Department of Nuclear Medicine, Chonnam National University Hospital, 42 Jebong-ro, Dong-gu, Gwangju, 61469 South Korea
| | - Jahae Kim
- 2Department of Nuclear Medicine, Chonnam National University Hospital, 42 Jebong-ro, Dong-gu, Gwangju, 61469 South Korea
| | - Ho-Chun Song
- 2Department of Nuclear Medicine, Chonnam National University Hospital, 42 Jebong-ro, Dong-gu, Gwangju, 61469 South Korea
| | - Seong Young Kwon
- 1Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 58128 South Korea
| |
Collapse
|
8
|
Han YH, Jeong HJ, Sohn MH, Lee SY, Lim ST. Radioiodine ablation in thyroid cancer patients: renal function and external radiation dose rate at discharge according to patient preparation. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING : OFFICIAL PUBLICATION OF THE ITALIAN ASSOCIATION OF NUCLEAR MEDICINE (AIMN) [AND] THE INTERNATIONAL ASSOCIATION OF RADIOPHARMACOLOGY (IAR), [AND] SECTION OF THE SOCIETY OF RADIOPHARMACEUTICAL CHEMISTRY AND BIOLOGY 2018. [PMID: 29521481 DOI: 10.23736/s1824-4785.18.03029-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND An elevated thyroid stimulating hormone (TSH) level is essential for the uptake of radioiodine into thyroid remnants and residual thyroid cancer in patients undergoing high-dose radioiodine therapy (HD-RIT). Recently, the use of recombinant human thyroid stimulating hormone (rh-TSH) has increased in preference over the conventional method of thyroid hormone withdrawal (THW). However, the clinical influences of the two methods, aside from the therapeutic effects, have not been widely evaluated. The aim of this work was to investigate the influences of the two methods, particularly on the renal function and external radiation dose rate (EDR) from patients undergoing HD-RIT. METHODS From February 2012 to November 2016, 667 patients (M:F=138:529, mean age: 47.7±11.8 years), who underwent first HD-RIT (120, 150, or 180 mCi, 1 mCi=37 MBq) for ablation of remnant thyroid tissue or residual thyroid cancer, were enrolled. Patients who were proven to have distant metastasis to lung or bone were excluded. Low- to high-risk patients based on 2015 American thyroid association management guidelines who underwent first HD-RIT in our department were included. The period from total thyroidectomy to HD-RIT was limited within 12 months. The following parameters were collected and evaluated: age, gender, histology type and TNM stage of thyroid cancer, glomerular filtration rate on the admission day for total thyroidectomy (baseline GFR), GFR on the day of HD-RIT (follow-up GFR), thyroglobulin (Tg) and TSH levels on the day of HD-RIT, and EDR on the discharge day after HD-RIT. RESULTS There were 386 patients using the THW method and 281 patients choosing the rh-TSH method. The baseline GFR of the THW group (106±16 mL/min/1.73 m2) and that of the rh-TSH group (104±17 mL/min/1.73 m2) were within normal limits and there was no significant difference. However, follow-up GFR of the THW group (84±17 mL/min/1.73 m2) was much lower than that of the rh-TSH group (104±16 mL/min/1.73 m2) (P=0.000). In the THW group, the follow-up GFR decreased significantly (P=0.000), yet the follow-up GFR of the rh-TSH group was not statistically different when compared with its baseline GFR (P=0.142). EDRs were lower in all rh-TSH subgroups compared to those of THW subgroups with statistical significance. Tg and TSH levels were not different between the two groups, excluding a few small-sized subgroups analyses. CONCLUSIONS In this retrospective analysis of renal function and EDR, the use of rh-TSH appears to help maintain renal function and finally decrease EDR in contrast to the THW method when undergoing HD-RIT.
Collapse
Affiliation(s)
- Yeon-Hee Han
- Department of Nuclear Medicine, Research Institute of Clinical Medicine of Chonbuk National University, Jeonju, Jeonbuk, South Korea.,Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Jeonbuk, South Korea.,Cyclotron Research Center, Jeonju, Jeonbuk, South Korea.,Molecular Imaging and Therapeutic Medicine Research Center, Jeonju, Jeonbuk, South Korea.,Chonbuk National University Medical School and Hospital, Jeonju, Jeonbuk, South Korea
| | - Hwan-Jeong Jeong
- Department of Nuclear Medicine, Research Institute of Clinical Medicine of Chonbuk National University, Jeonju, Jeonbuk, South Korea.,Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Jeonbuk, South Korea.,Cyclotron Research Center, Jeonju, Jeonbuk, South Korea.,Molecular Imaging and Therapeutic Medicine Research Center, Jeonju, Jeonbuk, South Korea.,Chonbuk National University Medical School and Hospital, Jeonju, Jeonbuk, South Korea
| | - Myung-Hee Sohn
- Department of Nuclear Medicine, Research Institute of Clinical Medicine of Chonbuk National University, Jeonju, Jeonbuk, South Korea.,Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Jeonbuk, South Korea.,Cyclotron Research Center, Jeonju, Jeonbuk, South Korea.,Molecular Imaging and Therapeutic Medicine Research Center, Jeonju, Jeonbuk, South Korea.,Chonbuk National University Medical School and Hospital, Jeonju, Jeonbuk, South Korea
| | - Sun Y Lee
- Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Jeonbuk, South Korea.,Chonbuk National University Medical School and Hospital, Jeonju, Jeonbuk, South Korea.,Department of Radiation Oncology, Research Institute of Clinical Medicine of Chonbuk National University, Jeonju, Jeonbuk, South Korea
| | - Seok T Lim
- Department of Nuclear Medicine, Research Institute of Clinical Medicine of Chonbuk National University, Jeonju, Jeonbuk, South Korea - .,Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Jeonbuk, South Korea.,Cyclotron Research Center, Jeonju, Jeonbuk, South Korea.,Molecular Imaging and Therapeutic Medicine Research Center, Jeonju, Jeonbuk, South Korea
| |
Collapse
|
9
|
Yang M, Bai L, Yu W, Sun X, Xu G, Guan R, Yang Y, Qiu M, Zhang Y, Tian J, Fang H. Expression of autophagy-associated proteins in papillary thyroid carcinoma. Oncol Lett 2017; 14:411-415. [PMID: 28693184 DOI: 10.3892/ol.2017.6101] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2015] [Accepted: 03/21/2017] [Indexed: 12/16/2022] Open
Abstract
The present study was designed to assess the protein expression of the autophagy-associated genes, Beclin-1 and microtubule-associated protein 1 light chain 3 (LC3)-II, as well as the association with clinicopathological features in papillary thyroid carcinoma (PTC). A total of 50 subjects were recruited, including 50 human PTC samples and paired adjacent noncancerous tissue samples. The protein expression of Beclin-1 and LC3-II was analyzed using immunohistochemistry and western blotting. Beclin-1 and LC3-II expression in PTC tissues significantly reduced compared with normal tissues (P<0.05). Expression of Beclin-1 and LC3-II was associated with lymph node metastasis of PTC (P<0.05), but had no association with age, gender, tumor size, tumor number and Tumor-Node-Metastasis stage (P>0.05). Expression of Beclin-1 and LC3-II were positively correlated (r=0.327;P=0.020) in PTC. In conclusion, the activity of autophagy was declined in PTC; this decrease in autophagic capacity may be associated with tumorigenesis and the development of PTC.
Collapse
Affiliation(s)
- Meiliu Yang
- Department of Medical Experimental Center, North China University of Science and Technology, Tangshan, Hebei 063000, P.R. China
| | - Lu Bai
- Department of Medical Experimental Center, North China University of Science and Technology, Tangshan, Hebei 063000, P.R. China
| | - Wu Yu
- Department of Surgery, Qianan Yejituo Hospital, Qianan, Hebei 064400, P.R. China
| | - Xueling Sun
- Department of Endocrinology, Tangshan Worker Hospital, Tangshan, Hebei 063000, P.R. China
| | - Gang Xu
- Department of Burn, Tangshan Worker Hospital, Tangshan, Hebei 063000, P.R. China
| | - Ruhua Guan
- Department of Endocrinology, Hebei Yanda Hospital, San He, Hebei 065201, P.R. China
| | - Ying Yang
- Department of Endocrinology, Tangshan Worker Hospital, Tangshan, Hebei 063000, P.R. China
| | - Mingyue Qiu
- Department of Endocrinology, Tangshan Worker Hospital, Tangshan, Hebei 063000, P.R. China
| | - Yazhong Zhang
- Department of Endocrinology, Tangshan Worker Hospital, Tangshan, Hebei 063000, P.R. China
| | - Jinli Tian
- Department of Endocrinology, Tangshan Worker Hospital, Tangshan, Hebei 063000, P.R. China
| | - Hui Fang
- Department of Endocrinology, Tangshan Worker Hospital, Tangshan, Hebei 063000, P.R. China
| |
Collapse
|